Iodine Deficiency Clinical Trial
— DFS-IoFA-2Official title:
Evaluation of the Acceptability and Nutritional Effects of Double-fortified Salt Containing Folic Acid and Iodine Among Ethiopian Women of Reproductive Age - a Household-randomized, Controlled, Community-based Trial
Verified date | April 2024 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overarching objective of this two-phase project is to assess the effects of fortifying iodized salt with folic acid on improving women's folate status. Folate insufficiency is the primary risk factor for neural tube defects (NTDs), which are highly prevalent in Ethiopia. The purposes of Phase 2 of the project, described herein, are to complete a community-based, randomized, dose-response intervention trial of edible salt fortified with just iodine or iodine and one of two levels of folic acid among non-pregnant women of reproductive age (WRA), We will assess the effects of the intervention on women's discretionary salt intakes, markers of folate and iodine status, and incidence of any adverse events.
Status | Active, not recruiting |
Enrollment | 360 |
Est. completion date | September 30, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 49 Years |
Eligibility | Inclusion Criteria: - Non-pregnant - Using long-acting contraceptive - Intending to remain in study community for at least six months - Willing to use study salt for all household food preparation and seasoning - Signed, informed consent Exclusion Criteria: - Pregnant - Not using long-acting contraceptive - Acute or chronic disease that affects dietary intake or folate metabolism - Hypertension - Medications that potentially interfere with folate metabolism - Folic acid-containing vitamin supplements - Macrocytic anemia or moderate/severe non-macrocytic anemia. - Mid-upper arm circumference <23 cm and breast feeding an infant <6 months of age |
Country | Name | City | State |
---|---|---|---|
Ethiopia | Ethiopian Public Health Institute | Addis Ababa |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis | Ethiopian Public Health Institute, Nutrition International, University of California, San Francisco, University of Rhode Island |
Ethiopia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Blood pressure | Resting systolic and diastolic blood pressure will be measured at baseline and at the time of subsequent blood drawings. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Primary | Red blood cell folate | Red blood cell (RBC) folate concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention. RBC folate concentration will be will be determined by using a microbiological assay. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Primary | Serum folate | Serum folate concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention, by using a microbiological assay. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Primary | Serum homocysteine | Serum homocysteine concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Primary | Serum thyroglobulin | Serum thyroglobulin concentration will be measured on three occasions in each participant: 1) before the start of the intervention, 2) at a randomly assigned mid-point between 4 and 20 weeks after the start of the intervention, and 3) between 24-26 weeks after the start of the intervention. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Primary | 24-hour urinary iodine excretion | 24-hour urinary iodine excretion will be measured prior to the start of the intervention and at a second time time at least 4 weeks after the start of the intervention. | Before and during the intervention | |
Primary | Serious adverse events | Serious adverse events requiring an overnight stay in a clinical facility or resulting in disability, or death will be recorded during each bi-weekly home visit. | Throughout the course of the intervention, total of 26 weeks | |
Secondary | Hemoglobin concentration | Hemoglobin concentration in venous blood will be measured at three time points, using an automated hematology analyzer. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Serum B12 | Serum concentration of cyanocobalamin will be measured at three time points. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Serum transcobalamin | Serum concentration of transcobalamin will be measured at three time points. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Serum methyl malonic acid | Serum concentration of methyl malonic acid will be measured at three time points. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Serum unmetabolized folic acid | Unmetabolized folic acid will be measured in serum at three time points. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Serum glucose | Fasting serum glucose concentration will be measured at three time points. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Serum insulin | Fasting serum insulin concentration will be measured at three time points. | Baseline (pre-intervention), intermediate time point (between 4-20 weeks), and end line (24-26 weeks) | |
Secondary | Discretionary salt intake | Discretionary salt intake will be measured by full-day, in-home weighed dietary records at one or two time points after the start of the intervention | After the start of the intervention, between 4-20 weeks | |
Secondary | Urinary sodium excretion | 24-hour urinary sodium excretion will be measured prior to the start of the intervention and at a second time time at least 4 weeks after the start of the intervention. | Before and between 4-20 weeks after the start of the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00791466 -
Maternal Iodine Supplementation and Effects on Thyroid Function and Child Development
|
N/A | |
Completed |
NCT05724251 -
Effect of Iodine Deficiency on Periodontitis
|
||
Completed |
NCT01349634 -
The Effects of Iodized Salt on Cognitive Development in Ethiopia
|
N/A | |
Completed |
NCT05170997 -
Strategies to Improve Iodine Status in Early Pregnancy
|
N/A | |
Completed |
NCT03731312 -
Variability of Daily Iodine Intake: The Effects of Intra- and Inter-individual Variability in Iodine Nutrition Studies
|
||
Not yet recruiting |
NCT05901766 -
Effect of Iodine-containing Multiple Micronutrient During Lactation on Infant Neurodevelopment
|
Phase 4 | |
Completed |
NCT02280330 -
Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months
|
Phase 4 | |
Completed |
NCT01985204 -
Iodine Supplementation in Obesity
|
N/A | |
Withdrawn |
NCT01301768 -
Group Education to Improve the Iodine Nutrition in Pregnancy: Cluster Randomized Trial
|
N/A | |
Completed |
NCT03279315 -
An Iodine Balance Experiment
|
N/A | |
Completed |
NCT01126125 -
Study of the Effect of Iodized Oil Supplementation During Infancy
|
N/A | |
Recruiting |
NCT00505479 -
Iodine Status in Pregnant Women and Their Newborns: is Congenital Hypothyroidism Related to Iodine Deficiency in Pregnancy?
|
N/A | |
Recruiting |
NCT05382793 -
Assessment of the Daily Average Requirement of Iodine in Lactating Women
|
N/A | |
Completed |
NCT03078140 -
Iodine Supplement Strategies Between Routine Iodine Supplementation and Selective Iodine Supplementation
|
N/A | |
Completed |
NCT05685056 -
Nutrition & Food Choices in Early Pregnancy
|
N/A | |
Completed |
NCT05792241 -
Acceptability and Nutritional Impact of Double-fortified Salt Containing Iodine and Folic Acid - Phase 1
|
||
Completed |
NCT03602404 -
Estimating Usual Iodine Intake From Spot Urinary Iodine Concentrations
|
||
Completed |
NCT02196337 -
Salt Iodization: Meeting the Needs of Pregnancy, Lactation and Infancy
|
N/A | |
Completed |
NCT03215680 -
Climat Impact on Urinary Iodine Concentration
|
||
Recruiting |
NCT03377218 -
Potential Preventive Effect of Selenium on Iodine-induced Thyroid Autoimmunity During Pregnancy
|
N/A |